Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants - IM039-1001
Updated: 2 May, 2023 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Participants must be ethnically Japanese (both biological parents are ethnically Japanese). - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory determinations. - Body mass index (BMI) between 18 and 30 kg/m2, inclusive, at screening. Exclusion Criteria: - Any significant acute or chronic medical illness. - Any major surgery within 4 weeks prior to study drug administration, or any surgery planned during the course of the study. - Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status (eg, history of splenectomy). Other protocol-defined inclusion/exclusion criteria apply.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
